Amol Akhade, Senior Consultant at Fortis Hospitals Mumbai, shared a post on LinkedIn:
“Apart from updates on Destiny Trials ( DB11 , 09 , 05 ) and Updates on various new Endocrine trials ( Ember3 , evERA serena 6 , Viktoria1 ) what’s new data to look forward at SABCS25:
1- Her2climb 05
Tucatinib making entry in First line MBC
2- Ascent 07
SG making entry in first line Metastatic HR+Ve Her2 low BC
3- Giredestrant ( SERD ) in adjuvant EBC
4- role of pre operative RT along with pembrolizumab and chemo in HR +ve Her2 low EBC
And off course
The Famous
View from Trenches
What to do on Monday Morning.”
More posts featuring Amol Akhade on OncoDaily.
